NEW YORK (GenomeWeb News) – Labcyte said today that it is collaborating with AstraZeneca on applying its acoustic liquid handling technology to mass spec-based drug discovery work.

The collaboration will focus on using Labcyte's technology for direct loading of samples into mass spectrometers, which, the company said, could enable high-throughput, low-cost, label-free mass spec analyses. AstraZeneca aims via the project to expand such mass spec analyses throughout its entire drug discovery and development process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.